Portfolio news 0

CAMBRIDGE, MA – November 3, 2026 – Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced an upcoming poster presentation of first-in-human clinical data from a Phase 1 study of NG-348 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2026, being held from November 4–8, in Phoenix, Arizona.

NG-348 is an intravenously delivered oncolytic immunotherapy designed to drive intratumoral expression of two membrane-bound proteins that provide key signals for T cell activation: anti-CD3 single-chain variable fragment (scFv) and CD80. Tumor-cell surface expression of these molecules triggers antigen independent T-cell activation within the tumor microenvironment (TME), enabling direct tumor cell killing. By combining direct T cell engagement with oncolysis, NG-348 stimulates a robust anti-tumor response locally within the TME while also offering the potential to overcome immunotherapy resistance. The Phase 1 study assessed the safety, tolerability and preliminary anti-tumor effects of NG-348 monotherapy in patients with metastatic or advanced epithelial tumors refractory to standard therapies.

Poster Presentation Details:

Title: Phase 1 first-in-human study of NG-348 – an oncolytic adenovirus expressing CD80 and anti-CD3 scFv in patients with advanced epithelial tumors

Abstract: #497

Date and Time: November 6, 2026, 10 a.m. – 2 p.m. and 5 p.m. – 7 p.m. MT

Location: Phoenix Convention Center, North Exhibition Halls 4–6